Corporate

  • Nov. 14, 2012 biOasis Enters Into a Research & Evaluation Agreement with MedImmune

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) announced today that it has entered into a research and evaluation agreement with MedImmune (MedImmune), the global biologics arm of AstraZeneca. Under the terms of this collaboration, biOasis will conduct certain experiments at MedImmune’s expense with the objective of demonstrating that biOasis’s Transcend technology can deliver to the… Read more »

  • Sep. 27, 2012 Experienced Life Science Executive Joins biOasis Board of Directors

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (BTI) is pleased to announce that Mr. Gregory Gubitz has joined the Board of Directors of the Company. Mr. Gubitz is a seasoned life science executive and lawyer, with significant transaction and investment experience. Mr. Gubitz was most recently Senior Vice President, Corporate Development and General Counsel of Biovail… Read more »

  • Jun. 18, 2012 biOasis Enters Research & Evaluation Agreement with Abbott

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) announced today that it has entered into an agreement with Abbott, to evaluate biOasis’s Transcend technology. As consideration for entering into this agreement, undertaking certain activities, and funding a number of experiments, Abbott has been granted certain options to obtain a license to biOasis’ Transcend technology under mutually… Read more »

  • Feb. 16, 2012 biOasis named to TSX Venture 50®

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) announces it has been named one of the 2012 TSX Venture 50® companies. The TSX Venture 50® includes the top 10 companies in 5 major industry sectors that have been identified as leaders in providing shareholder value on Canada’s junior stock exchange. “We are very proud to be… Read more »

  • Jan. 17, 2012 biOasis Enters Investor Relations Agreement with Brisco Capital Partners Corp.

    Vancouver, B.C.–(Business Wire)– biOasis Technologies Inc. (TSX.V: BTI) (the “Company”) is pleased to announce that it has Brisco Capital Partners Corp. (“Brisco”) to provide investor relations, subject to regulatory approval. Brisco will initiate and maintain contact with the financial community, shareholders, investors and other stakeholders for the purpose of increasing awareness of the Company and… Read more »

  • Nov. 24, 2011 biOasis Enters Research, Evaluation and Option Agreement with Shire Human Genetic Therapies, Inc.

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) announced today that it has entered into a research, evaluation and option agreement with Shire Human Genetic Therapies, Inc. (Shire) to evaluate biOasis’s Transcend technology in the area of lysosomal storage disorders (LSDs). In connection with this agreement, biOasis and Shire are undertaking certain experiments at their own… Read more »

  • Aug. 18, 2011 2011-2012 Board of Directors and Officers

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) announces its board of directors elected by the shareholders at its recently held Annual General Meeting held July 26, 2011: Robin Hutchison* Chairman of the Board David Clark CATerry Pearson Ph.D.Chris Fibiger PH.D.Michael Hutchison Q.C.Ron Erickson* Chairman of the Audit CommitteeMember of the Audit CommitteeMember of the Compensation,… Read more »

  • Aug. 10, 2011 biOasis announces completion of acquisition of Intellectual Property

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) (the “Company”) announces that its wholly owned subsidiary biOasis Advanced Technologies Inc. (“BAT”) has completed the acquisition of certain Intellectual Property pursuant to a Worldwide Assignment dated June 16, 2011 on terms as previously disclosed. On August 5, 2011, the closing date, the Company paid $25,000 in cash… Read more »

  • Aug. 5, 2011 biOasis announces acquisition of Intellectual Property

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) (the “Company”) announces that its wholly owned subsidiary biOasis Advanced Technologies Inc. has entered into a worldwide assignment (the “Assignment”) to acquire certain Intellectual Property. Pursuant to the Assignment, the Company will pay $25,000 in cash and will issue 350,000 warrants at an exercise price of $0.575 and… Read more »

  • Jun. 24, 2011 biOasis Director Resigns

    Vancouver, BC–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) announces that Mr. David Howard has resigned from the board of directors and audit committee. Mr. Howard has been a member of the board since August 9th, 2010. “We would like to thank David for his valuable contribution and service on the board of directors of the Company,”… Read more »